This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.EB Schmidt , H Arnesen , R de Caterina (2005) Marine n-3 polyunsaturated fatty acids and coronary heart disease – Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res 115, 163–170.
3.TA Mori & LJ Beilin (2001) Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 12, 11–17.
8.MC Morris , F Sacks & B Rosner (1993) Does fish-oil lower blood-pressure – a metaanalysis of controlled trials. Circulation 88, 523–533.
9.GE McVeigh , GM Brennan , JN Cohn (1994) Fish-oil improves arterial compliance in non-insulin-dependent diabetes-mellitus. Arterioscler Thromb 14, 1425–1429.
11.JP Chin (1994) Marine oils and cardiovascular reactivity. Prostaglandins Leukot Essent Fatty Acids 50, 211–222.
12.TA Mori , GF Watts , V Burke (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102, 1264–1269.
15.PC Calder (2001) Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36, 1007–1024.
17.TA Mori & LJ Beilin (2004) Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 6, 461–467.
18.PC Calder (2012) The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 56, 1073–1080.
19.CN Serhan & NA Petasis (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111, 5922–5943.
20.E Mas , RJ Woodman , V Burke (2010) The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: results from two placebo-controlled interventions. Free Radic Res 44, 983–990.
23.HC Bucher , P Hengstler , C Schindler (2002) n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112, 298–304.
25.SP Whelton , J He , PK Whelton (2004) Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 93, 1119–1123.
27.D Mozaffarian , CL Bryson , RN Lemaitre (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 2015–2021.
28.K He , YQ Song , ML Daviglus (2004) Fish consumption and incidence of stroke – A meta-analysis of cohort studies. Stroke 35, 1538–1542.
35.D Mozaffarian , R Marchioli , A Macchia (2012) Fish oil and postoperative atrial fibrillation the omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. Jama-J Am Med Assoc 308, 2001–2011.
37.HO Dickinson , JM Mason , DJ Nicolson (2006) Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24, 215–233.
38.RS Dokholyan , CM Albert , LJ Appel (2004) Trial of omega-3 fatty acids for prevention of hypertension. Am J Cardiol 93, 1041–1043.
40.P Singer , S Melzer , M Goschel (1990) Fish oil amplifies the effect of propranolol in mild essential-hypertension. Hypertension 16, 682–691.
43.TA Mori , DQ Bao , V Burke (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253–260.
46.D Mozaffarian , A Geelen , IA Brouwer (2005) Effect of fish oil on heart rate in humans – A meta-analysis of randomized controlled trials. Circulation 112, 1945–1952.
49.JH Christensen & EB Schmidt (2001) n-3 Fatty acids and the risk of sudden cardiac death. Lipids 36, S115–S118.
51.A Leaf , JX Kang , YF Xiao (2003) Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107, 2646–2652.
54.WS Harris & D Bulchandani (2006) Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17, 387–393.
56.RJ Woodman , TA Mori , V Burke (2003) Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 26, 253.
58.S Lahdenpera , M Syvanne , J Kahri (1996) Regulation of low-density lipoprotein particle sire distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39, 453–461.
59.DC Chan , GF Watts , TA Mori (2002) Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 32, 429–436.
60.CE Friedberg , MJFM Janssen , RJ Heine (1998) Fish oil and glycemic control in diabetes – A meta-analysis. Diabetes Care 21, 494–500.
63.TA Mori , LJ Beilin , V Burke (1997) Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 17, 279–286.
67.CN Serhan (2005) Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 8, 115–121.
68.CN Serhan (2005) Novel omega-3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 105, 7–21.
69.CN Serhan , SD Brain , CD Buckley (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21, 325–332.
70.CN Serhan & N Chiang (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13, 632–640.
71.RR Ji , ZZ Xu , G Strichartz (2011) Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 34, 599–609.
72.CN Serhan , N Chiang & TE Van Dyke (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349–361.
73.I Tabas (2010) Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10, 36–46.
74.E Mas , KD Croft , P Zahra (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58, 1476–1484.
75.F Thies , JMC Garry , P Yaqoob (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477–485.
77.TA Mori , RJ Woodman , V Burke (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772–781.
78.TA Mori , IB Puddey , V Burke (2000) Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox Rep 5, 45–46.
79.GL Milne , HY Yin , KD Hardy (2011) Isoprostane Generation and Function. Chem Revi 111, 5973–5996.
80.AE Barden , TA Mori , JA Dunstan (2004) Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Radic Res 38, 233–239.